A leading oncology hospital chain saw its stock fall after a major foreign investor sold a significant stake. Despite this, mutual funds stepped in as buyers. Financially, revenue grew strongly, though profit declined, while nationwide cancer care leadership and infrastructure remain robust.
The shares of this healthcare company plummeted up to 4 percent in today’s trading session after a prominent foreign company offloaded 79,41,913 equity shares via a bulk deal.
With a market capitalization of Rs 9,658.00 crore, the shares of HealthCare Global Enterprises Ltd were trading at Rs 692.75 per share, decreasing around 0.44 percent as compared to the previous closing price of Rs 695.80 apiece.
Bluk deal
The shares of HealthCare Global Enterprises Ltd have seen bearish movement after a prominent foreign company, Aceso Company Pte Ltd, offloaded 79,41,913 equity shares, which is equivalent to a 5.69 percent stake at an average of Rs 695 per share in Healthcare Global Enterprises, for Rs 551.96 crore.
However, Motilal Oswal MF, Plutus Wealth Management, Morgan Stanley, Nippon India Mutual Fund, and Axis Mutual Fund bought 6,952,700 equity shares at an average price of Rs 695, which is equivalent to Rs 483.21 crore. As of June 2025, Aceso Company Pte Ltd holds 1,22,06,043 equity shares, which is equivalent to 8.76 percent of the company.
Also Read: Chemical stock falls 4% after reporting gas leak at Gujarat plant leaves 1 dead, 13 hospitalised
Financial & operational Highlights
Looking forward to the company’s financial performance, revenue increased by 17 percent from Rs 525.58 crore in Q1FY25 to Rs 613.16 crore in Q1FY26. Further, during the same time frame, net profit decreased by 56 percent from Rs 13.63 crore to Rs 5.98 crore.
Healthcare Global Enterprises (HCG) has 25 centers across 19 cities and a presence in 10 states, covering 55% of the addressable market. Backed by over 400 oncologists, advanced infrastructure with PET-CTs, LINACs, robots, and 2,500+ beds, HCG ensures strong leadership in cancer care with 3.7 lakh+ new registrations in five years.
HCG has established leadership in ~90 percent of the 18 cities it operates in, with 21+ cancer centers, making it the largest oncology chain in India. Its footprint is 1.5x larger than the nearest competitor, with strong dominance in both metro and non-metro markets, ensuring widespread access and last-mile cancer care across the country.
HealthCare Global Enterprises is one of India’s premier specialty cancer care hospitals, providing advanced diagnostic and treatment facilities to improve patient outcomes. The company operates on a vision of adding life to years by redefining healthcare through global innovation and value-based medicine.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
